Summary:
In patients with type 2 diabetes (T2DM), dapagliflozin treatment over 4 years
significantly improved coronary flow reserve (CFR) by 30% and reduced epicardial adipose tissue (EAT) thickness compared to placebo after treatment, though it was associated with no significant adverse cardiovascular effects.
| PICO | Description |
|---|---|
| Population | Adults with type 2 diabetes mellitus (T2DM) at risk for cardiovascular diseases and undergoing treatment for at least 4 years. |
| Intervention | Dapagliflozin treatment given continuously over a 4-year period. |
| Comparison | Placebo treatment with additional intervention initiated after the 4-year period for comparisons. |
| Outcome | Dapagliflozin resulted in a 30% sustained improvement in coronary flow reserve (CFR) and significant reduction in epicardial adipose tissue (EAT) thickness, highlighting its long-term cardiovascular benefits and role in CV risk reduction in T2DM patients. |
Source: Francesca Cinti, et al. “Coronary flow reserve increase after 4-year dapagliflozin treatment in patients with type 2 diabetes: the DAPAHEART follow-up study.” Read article here.
